^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TQB2825
i
Other names: TQB2825, TQB-2825
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Sino Biopharm
Drug class:
CD20 inhibitor, CD3 agonist
Related drugs:
2ms
Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma (clinicaltrials.gov)
P3, N=228, Not yet recruiting, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
New P3 trial
|
cisplatin • carboplatin • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • TQB2825
4ms
Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological Malignancies (clinicaltrials.gov)
P1, N=75, Not yet recruiting, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
New P1 trial
|
TQB2825
7ms
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
P1/2, N=150, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • oxaliplatin • TQB2825
9ms
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
P2, N=55, Recruiting, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
gemcitabine • oxaliplatin • TQB2825
9ms
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
P2, N=55, Not yet recruiting, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
New P2 trial
|
gemcitabine • oxaliplatin • TQB2825
10ms
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
P1/2, N=150, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P1/2 trial
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • oxaliplatin • TQB2825
over3years
Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors (clinicaltrials.gov)
P1, N=180, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
New P1 trial
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
TQB2825
Share via
